- Synthesis and cytotoxic evaluation of some new 1-(6- chloropyridazin-3-Yl)-3-H/Alkyl-4-phenyl-1H-pyrazol- 5-amines and their derivatives
-
Synthesis of new 1-(6-chloropyridazin-3-yl)-3-H/alkyl-4-phenyl-1H-pyrazol-5-amines (3) was accomplished by the reaction of 3-chloro-6-hydrazinopyridazine (1) with differently substituted β-ketonitriles (2) under reflux in ethanol. Subsequently, a series of 6-amino derivatives (4, 5 and 6) was synthesized by amino-de-halogenation of 3 with secondry cyclic amines e.g. pyrrolidine, piperidine and morpholine respectively. Structures of all the compounds were established by IR, NMR (1H, 13C and 19F) and mass spectral data, and elemental analysis. All the compounds were screened for their cytotoxic effects against three cancer cell lines (SB-ALL, NALM-6, MCF-7) using colorimetric MTT assay.
- Mamta,Aggarwal, Ranjana,Smith, Jessie,Sadana, Rachna
-
-
- Ametoctradin is a Potent Qo Site Inhibitor of the Mitochondrial Respiration Complex III
-
Ametoctradin is a new Oomycete-specific fungicide under development by BASF. It is a potent inhibitor of the bc1 complex in mitochondrial respiration. However, its detailed action mechanism remains unknown. In the present work, the binding mode of ametoctradin was first uncovered by integrating molecular docking, MD simulations, and MM/PBSA calculations, which showed that ametoctradin should be a Qo site inhibitor of bc1 complex. Subsequently, a series of new 1,2,4-triazolo[1,5-a]pyrimidine derivatives were designed and synthesized to further understand the substituent effects on the 5- and 6-position of 1,2,4-triazolo[1,5-a]pyrimidine. The calculated binding free energies (ΔGcal) of newly synthesized analogues as Qo site inhibitors correlated very well (R2 = 0.96) with their experimental binding free energies (ΔGexp). Two compounds (4a and 4c) with higher inhibitory activity against porcine SQR than ametoctradin were successfully identified. The structural and mechanistic insights obtained from the present study will provide a valuable clue for future designing of a new promising bc1 inhibitor.
- Zhu, Xiaolei,Zhang, Mengmeng,Liu, Jingjing,Ge, Jingming,Yang, Guangfu
-
p. 3377 - 3386
(2015/04/14)
-
- HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
-
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
- -
-
Page/Page column 19
(2012/11/08)
-